Compare EVAX & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVAX | IXHL |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | Denmark | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.7M | 49.1M |
| IPO Year | 2021 | N/A |
| Metric | EVAX | IXHL |
|---|---|---|
| Price | $5.85 | $0.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.33 | N/A |
| AVG Volume (30 Days) | 98.3K | ★ 25.1M |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,650,000.00 | $12,000.00 |
| Revenue This Year | $128.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 132.17 | N/A |
| 52 Week Low | $1.20 | $0.08 |
| 52 Week High | $12.15 | $2.25 |
| Indicator | EVAX | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 56.30 |
| Support Level | $5.72 | $0.37 |
| Resistance Level | $6.70 | $0.44 |
| Average True Range (ATR) | 0.47 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 50.26 | 55.01 |
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.